{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:49:44Z","timestamp":1782100184202,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100016912","name":"Merck Sharp and Dohme France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014088","name":"AstraZeneca France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014088","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40801-026-00551-z","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:30:20Z","timestamp":1776069020000},"page":"211-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["First Real-World Data of Olaparib Combination Treatment with Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC): Descriptive Analysis of 154 Patients Enrolled in the Early Access Program in France"],"prefix":"10.1007","volume":"13","author":[{"given":"Louis Marie","family":"Dourthe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"Guillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Vassal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyad","family":"Kazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Coeffic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rebischung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Suau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Lahouegue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Aboulabbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8296-3559","authenticated-orcid":false,"given":"Am\u00e9lie","family":"Falabr\u00e8gues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassiba","family":"Ould Lahsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"551_CR1","unstructured":"Institut National du Cancer. Le cancer de la prostate: les cancers les plus fr\u00e9quents (e-cancer.fr). www.e-cancer.fr. Accessed 3 Jan 2025."},{"key":"551_CR2","unstructured":"Institut National du Cancer (INCa). Panorama des cancers en France. \u00c9dition 2024. Panorama des cancers en France - \u00e9dition 2024 - Ref : PANOKFR 2024. https:\/\/www.e-cancer.fr\/Expertises-et-publications\/Catalogue-des-publications\/Panorama-des-cancers-en-France-edition-2024. Accessed 1 Apr 2025."},{"key":"551_CR3","unstructured":"Sant\u00e9 Publique France. Bulletin \u00e9pid\u00e9miologique hebdomadaire. N\u00b0 12-13, 4 July 2023."},{"issue":"11","key":"551_CR4","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","volume":"65","author":"M Kirby","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180\u201392.","journal-title":"Int J Clin Pract"},{"key":"551_CR5","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Avis de la Commission de la Transparence (Transparency Committee) ZYTIGA\u00ae. Haute Autorit\u00e9 de Sant\u00e9; 2018."},{"issue":"8","key":"551_CR6","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1007\/s12325-021-01823-6","volume":"38","author":"ND Shore","year":"2021","unstructured":"Shore ND, Lalibert\u00e9 F, Ionescu-Ittu R, Yang L, Mahendran M, Lejeune D, et al. Real-world treatment patterns and overall survival of patients with metastatic castration-resistant prostate cancer in the US prior to PARP inhibitors. Adv Ther. 2021;38(8):4520\u201340.","journal-title":"Adv Ther"},{"issue":"9","key":"551_CR7","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1111\/j.1464-410X.2005.05821.x","volume":"96","author":"G Attard","year":"2005","unstructured":"Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241\u20136.","journal-title":"BJU Int"},{"issue":"7","key":"551_CR8","first-page":"F442","volume":"34","author":"G Ploussard","year":"2024","unstructured":"Ploussard G, Dariane C, Mathieu R, Baboudjian M, Barret E, Brureau L, et al. Recommandations fran\u00e7aises du Comit\u00e9 de canc\u00e9rologie de l\u2019AFU\u202f: actualisation 2024\u20132026: cancer de la prostate: traitement de la r\u00e9cidive et de la maladie m\u00e9tastatique: French AFU Cancer Committee Guidelines: update 2024\u20132026: treatment of recurrence and metastatic disease. Prog Urol. 2024;34(7):F442\u201379.","journal-title":"Prog Urol"},{"issue":"3","key":"551_CR9","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s11523-020-00720-2","volume":"15","author":"S Chowdhury","year":"2020","unstructured":"Chowdhury S, Bjartell A, Lumen N, Maroto P, Paiss T, Gomez-Veiga F, et al. Real-world outcomes in first-line treatment of metastatic castration-resistant prostate cancer: the Prostate Cancer Registry. Target Oncol. 2020;15(3):301\u201315.","journal-title":"Target Oncol"},{"issue":"5","key":"551_CR10","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375(5):443\u201353.","journal-title":"N Engl J Med"},{"issue":"4","key":"551_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O\u2019Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA damage response in cancer. Mol Cell. 2015;60(4):547\u201360.","journal-title":"Mol Cell"},{"issue":"22","key":"551_CR12","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"key":"551_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2147\/CMAR.S411023","volume":"16","author":"B Thapa","year":"2024","unstructured":"Thapa B, De Sarkar N, Giri S, Sharma K, Kim M, Kilari D. Integrating PARP inhibitors in mCRPC therapy: current strategies and emerging trends. Cancer Manag Res. 2024;16:1267\u201383.","journal-title":"Cancer Manag Res."},{"issue":"14","key":"551_CR14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI181062","volume":"134","author":"X Li","year":"2024","unstructured":"Li X, Zou L. BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality. J Clin Investig. 2024;134(14):e181062.","journal-title":"J Clin Investig"},{"issue":"9","key":"551_CR15","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):EVIDoa2200043.","journal-title":"NEJM Evid"},{"key":"551_CR16","unstructured":"AstraZeneca, AP LYNPARZA PROPEL. R\u00e9sum\u00e9 du rapport de synth\u00e8se final- Acc\u00e8s Pr\u00e9coce LYNPARZA (olaparib) 100 et 150 mg, comprim\u00e9 pellicul\u00e9, du 30\/03\/2023 au 25\/09\/2024 \u2013 Version 1.0. du 09\/05\/2025."},{"issue":"Suppl._8","key":"551_CR17","doi-asserted-by":"publisher","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(Suppl._8):viii61\u20135.","journal-title":"Ann Oncol"},{"issue":"1","key":"551_CR18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V, Arenare L, Lorusso D, Ronzino G, et al. Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol. 2020;156(1):38\u201344.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"551_CR19","doi-asserted-by":"publisher","first-page":"1094108","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094108.","journal-title":"Lancet Oncol"},{"issue":"12","key":"551_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","volume":"2","author":"MJ Schiewer","year":"2012","unstructured":"Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2(12):1134\u201349.","journal-title":"Cancer Discov"},{"issue":"4","key":"551_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/emmm.201303737","volume":"6","author":"MJ Schiewer","year":"2014","unstructured":"Schiewer MJ, Knudsen KE. AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. EMBO Mol Med. 2014;6(4):439\u201341.","journal-title":"EMBO Mol Med"},{"issue":"480","key":"551_CR22","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aam7479","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, et al. Androgen receptor inhibitor-induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017;10(480):eaam7479.","journal-title":"Sci Signal"},{"issue":"11","key":"551_CR23","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245\u201353.","journal-title":"Cancer Discov"},{"issue":"1","key":"551_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","volume":"8","author":"M Asim","year":"2017","unstructured":"Asim M, Tarish F, Zecchini HI, Sanjiv K, Gelali E, Massie CE, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8(1):374.","journal-title":"Nat Commun"},{"issue":"5781","key":"551_CR25","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1126\/science.1127196","volume":"312","author":"BG Ju","year":"2006","unstructured":"Ju BG, Lunyak VV, Perissi V, Garcia-Bassets I, Rose DW, Glass CK, et al. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science. 2006;312(5781):1798\u2013802.","journal-title":"Science"},{"issue":"11","key":"551_CR26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","volume":"3","author":"JF Goodwin","year":"2013","unstructured":"Goodwin JF, Schiewer MJ, Dean JL, Schrecengost RS, de Leeuw R, Han S, et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov. 2013;3(11):1254\u201371.","journal-title":"Cancer Discov"},{"issue":"312","key":"551_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac5671","volume":"7","author":"FL Tarish","year":"2015","unstructured":"Tarish FL, Schultz N, Tanoglidi A, Hamberg H, Letocha H, Karaszi K, et al. Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Sci Transl Med. 2015;7(312):312re11.","journal-title":"Sci Transl Med"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00551-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00551-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00551-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T03:19:23Z","timestamp":1782098363000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00551-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00551-z","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"26 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Louis Marie Dourthe declares potential conflicts of interest with AstraZeneca, Bayer, Merck Sereno, Ipsen, Pfizer, and Johnson & Johnson. Aline Guillot declares lectures for Ipsen. C\u00e9cile Vassal and Christine Rebischung have no conflicts of interest that are directly relevant to the content of this article. Eyad Kazan declares potential conflicts of interest with Pfizer, AstraZeneca, Janssen, Bristol Myers Squibb, Merck Sharp and Dohme Corp, and Roche. David Coeffic declares potential conflicts of interest with Novartis, Astellas, Bristol Myers Squibb, Merck Sharp and Dohme Corp, Roche, AstraZeneca, Janssen, and Pfizer. Am\u00e9lie Falabr\u00e8gues is employed by AstraZeneca and has no conflict of interest, nor any stocks or shares to declare. Delphine Suau, Amir Lahouegue, Sofia Aboulabbes, and Hassiba Ould Lahsen are employed by AstraZeneca and may hold shares.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Early access authorizations are granted by the HtA body since 1 July, 2021 for innovative medicines following an opinion from the ANSM as to their presumed efficacy and safety ratio. Ten months after this reform came into force through the 2021 French social security financing law, the HtA body and the ANSM issued a positive initial report on this procedure, which fast tracks and facilitates patient access to innovative medicines. This study followed the ethical principles set out in the Declaration of Helsinki. The process is formalized through the therapeutic use and data collection protocol (PUT-RD), which is a legal dossier required for each early access request and describes the methods of collecting patient data. All patient data collected are pseudonymized to respect the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The patients did receive a patient information leaflet from their physician. Patient consent was collected by the physician prior to administration of the medicine. This was mandatory and applied to all patients included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"The fEA is not a clinical trial. Therefore, there is no study conception, design, or material preparation. LMD, AG, CV, EK, DC, and CR are the most important contributors among prescribing physicians during the EA. HOL, DS, and AL designed the study and submitted the study project to prescribing physicians. LMD, AG, CV, EK, DC, CR, HOL, DS, and AL contributed to the data collection and report writing. SA, AF, HOL, AL, and DS analyzed the data. SA, AF, and HOL wrote the paper with input from all authors. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}